<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1613333</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Role of DNA methylation in regulating inflammatory cytokine expression in neonates with late-onset sepsis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Sankar</surname><given-names>Saranya</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Maruthai</surname><given-names>Kathirvel</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1848942/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Bobby</surname><given-names>Zachariah</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Adhisivam</surname><given-names>Bethou</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2518809/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Neonatology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)</institution>, <city>Puducherry</city>,&#xa0;<country country="in">India</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Paediatrics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)</institution>, <city>Puducherry</city>,&#xa0;<country country="in">India</country></aff>
<aff id="aff3"><label>3</label><institution>School of Medicine, Department of Infectious Diseases, Johns Hopkins University</institution>, <city>Baltimore</city>, <state>MD</state>,&#xa0;<country country="us">United States</country></aff>
<aff id="aff4"><label>4</label><institution>Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)</institution>, <city>Puducherry</city>,&#xa0;<country country="in">India</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Bethou Adhisivam, <email xlink:href="mailto:adhisivam1975@yahoo.co.uk">adhisivam1975@yahoo.co.uk</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-26">
<day>26</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1613333</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>04</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>23</day>
<month>10</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Sankar, Maruthai, Bobby and Adhisivam.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Sankar, Maruthai, Bobby and Adhisivam</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-26">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Neonatal sepsis is a major health issue, particularly in resource-poor areas. This study aimed to assess the role of DNA methylation in regulating the inflammatory cytokine expression in late-onset neonatal sepsis (LOS).</p>
</sec>
<sec>
<title>Methodology</title>
<p>We conducted a cross-sectional study comparing neonates with LOS (n=42) before and after 72 hours of antibiotic treatment (n=25) to healthy controls (HC) (n=42). We analysed DNA methylation patterns and inflammatory cytokine expression levels in both groups.</p>
</sec>
<sec>
<title>Results</title>
<p>DNA methylation analysis revealed hypomethylation in pro-inflammatory genes and hypermethylation in anti-inflammatory genes in LOS neonates. These patterns were shifted in follow-up group, with significant changes in inflammatory marker levels, including TNF-&#x3b1;, IFN-&#x3b3;, IL-10, and TGF-&#x3b2;. The gene expression results aligned with the DNA methylation findings, indicating that changes in the expression of inflammatory genes in late-onset neonatal sepsis (LONS) are influenced by DNA methylation. The results were further validated through an analysis of plasma cytokine levels. LOS cases showed elevated pro-inflammatory cytokines and reduced anti-inflammatory cytokines, except IL-10. In the follow-up group, pro-inflammatory cytokine levels decreased, while anti-inflammatory cytokines increased.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>DNA methylation regulates the expression of inflammatory cytokine genes in late-onset neonatal sepsis. Understanding these molecular changes could lead to better diagnostic and therapeutic approaches for managing neonatal sepsis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>neonatal sepsis</kwd>
<kwd>DNA methylation</kwd>
<kwd>inflammatory cytokines</kwd>
<kwd>infection</kwd>
<kwd>gene expression regulation</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was funded by Intramural Research Grant, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry -605 006, India (grant no. JIPMER/Neonatology/Intra-PhD/01/2019-20).</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="5"/>
<equation-count count="0"/>
<ref-count count="49"/>
<page-count count="9"/>
<word-count count="6016"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Microbial Immunology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Neonatal sepsis involves a compromised host immune response to microbes and their byproducts, leading to biochemical irregularities and organ dysfunction (<xref ref-type="bibr" rid="B1">1</xref>). Timely diagnosis poses a significant challenge in resource-constrained settings (<xref ref-type="bibr" rid="B2">2</xref>). Organ dysfunction arises from an imbalanced immune reaction to the infection within the host (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). In sepsis, infections occurring within the first 72 hours are termed early-onset sepsis (EOS), while those manifesting after 72 hours of birth are referred to as late-onset sepsis (LOS) (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>In this context, innate immune cells, such as neutrophils and monocytes, display heightened immune responses to invading pathogens, characterized by increased secretion of pro-inflammatory cytokines (<xref ref-type="bibr" rid="B5">5</xref>&#x2013;<xref ref-type="bibr" rid="B8">8</xref>). The intensity of the initial inflammatory response in sepsis is influenced by a combination of host genetic factors, pathogen load, and virulence. Because of this pro-inflammatory reaction, there is a subsequent release of anti-inflammatory cytokines, contributing to a state of immunosuppression (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>).</p>
<p>The initial line of defense against bacterial infections is orchestrated by pattern recognition receptors (PRRs) within innate immune cells (<xref ref-type="bibr" rid="B10">10</xref>). When bacterial antigens bind to PRRs, this triggers the activation of immune cells, resulting in significant alterations in the transcriptional activation of immune response genes, including various inflammatory cytokines and chemo attractants. These changes aim to provide a robust protective immune response within the host (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B12">12</xref>&#x2013;<xref ref-type="bibr" rid="B14">14</xref>). The equilibrium between pro-inflammatory and anti-inflammatory cytokines, as well as the involvement of specific immune cells, plays a crucial role in determining the host&#x2019;s ability to effectively clear pathogens (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Epigenetic mechanisms influence the expression of inflammatory cytokine genes by modifying them without changing the DNA sequence, potentially altering the host&#x2019;s immune response during infection (<xref ref-type="bibr" rid="B17">17</xref>). This may lead to immunosuppression in neonatal sepsis.</p>
<p>The impact of DNA methylation on the expression of immune response genes in neonatal sepsis remains unexplored, necessitating further investigation. Therefore, this study was undertaken to unveil and examine the influence of DNA methylation changes on the expression of inflammatory immune genes in response to late-onset neonatal sepsis.</p>
</sec>
<sec id="s2">
<title>Methodology</title>
<sec id="s2_1">
<title>Patient details</title>
<p>This cross-sectional comparative study was conducted following approval from the Institute Ethics Committee (ethical review no. JIP/IEC2019/0125). Informed consent was obtained from the parents of the enrolled neonates. The sample size was determined using OpenEpi to achieve a reliable difference in DNA methylation levels between the two groups with 5% significance and 95% power, factoring in a 25% dropout rate (<xref ref-type="bibr" rid="B18">18</xref>). As a result, a total of forty-two (n=42) neonates with late-onset sepsis (LOS) and forty-two (n=42) healthy neonates were included in the study.</p>
<p>The study included neonatal sepsis based on the presence of two or more clinical signs and symptoms, including difficulty feeding or feeding intolerance, abdominal distension, convulsions, abnormal posturing, hypotonia, no or minimal movement on stimulation, lethargy or drowsiness, irritability, bulging fontanelle, pus from the umbilical stump, abnormal temperature (&gt;37.5 &#xb0;C or &lt;36.5 &#xb0;C) or temperature instability, abnormal heart rate (&gt;180/min or &lt;100/min), severe chest in-drawing, increased oxygen requirement or need for ventilation support, grunting, apnea, capillary refill time (CRT) &gt; 3 seconds, mottled skin or other evidence of shock, and cyanosis. Laboratory markers used for diagnosis included white blood cell (WBC) count &lt; 4 &#xd7; 10<sup>9</sup> cells/L or &gt; 20 &#xd7; 10<sup>9</sup> cells/L, absolute neutrophil count &lt; 1.5 &#xd7; 10<sup>9</sup> cells/L, and C-reactive protein (CRP) &gt; 10 mg/L or &gt; 1 mg/dL. Since the blood samples were collected based on sepsis screening, the 42 neonates were classified as cases based on positive blood cultures, while those with negative cultures were classified as having clinical sepsis (n=23). Follow-up was conducted for 25 of the 42 cases due to study dropouts. The exclusion criteria for both cases and controls encompassed major congenital malformations, neonatal demise within 6 hours of admission, neonates weighing less than 1000 grams, and those with a gestational age of less than 30 weeks. Blood samples from the cases were collected both before initiating antibiotic treatment and after 72 hours of antibiotic treatment. The aim of the study was to analyze the inflammatory profile before starting antibiotic treatment and after 72 hours of antibiotic treatment. Since the sample collected before starting of antibiotics with suspicion of sepsis, the neonates with positive blood culture were considered as cases and the neonates with negative blood culture with signs and symptoms of sepsis were considered as clinical sepsis. Peripheral blood samples (2 mL each) were collected at the onset of suspected sepsis and again 72 hours after initiation of antibiotic treatment from newborns, with parental informed consent obtained during routine laboratory blood sampling. For DNA isolation whole blood sample of 0.5ml and RNA isolation 0.5ml was used. Remaining 1.0ml of blood sample was used for plasma separation at 3000 rpm for 10 minutes. After sample collection, the samples undergo separation into plasma, genomic DNA, and serum, which are then stored at -80 degrees Celsius. Subsequently, a batch analysis is conducted to eliminate any processing errors, and the results are generated once all the samples have been processed accordingly.</p>
<p>Healthy neonates, matched in terms of gestational age and gender, and undergoing blood collection for conditions such as thyroid screening, were selected as controls.</p>
</sec>
<sec id="s2_2">
<title>DNA methylation analysis</title>
<sec id="s2_2_1">
<title>Bisulfite conversion</title>
<p>The bisulfite conversion process was conducted following the guidelines of the EZ DNA Methylation Gold Kit (Zymo Research Inc., USA). Briefly, 500 ng of genomic DNA was subsequently extracted from the whole blood using a FavorGen genomic DNA isolation kit (<xref ref-type="bibr" rid="B19">19</xref>) from cases and controls underwent bisulfite conversion, which distinguishes unmethylated Cs by converting them to Us, while leaving methylated Cs unaffected. The converted DNA was subsequently stored at -20 &#xb0;C.</p>
</sec>
<sec id="s2_2_2">
<title>CpG Island location and primer design</title>
<p>The consensus sequence was obtained from PubMed and a publicly accessible source at TranspoGene (<ext-link ext-link-type="uri" xlink:href="https://www.ensembl.org/index.html">https://www.ensembl.org/index.html</ext-link>). To identify CpG islands (CGI) in the promoter region, the DBCAT tool (<ext-link ext-link-type="uri" xlink:href="http://dbcat.cgm.ntu.edu.tw/">http://dbcat.cgm.ntu.edu.tw/</ext-link>) was utilized. Methylation-specific polymerase chain reaction (MS-PCR) primers were designed using the MethPrimer tool with default settings. Additional information regarding the primers is available in <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table S1</bold></xref>.</p>
</sec>
<sec id="s2_2_3">
<title>Methylation-specific polymerase chain reaction</title>
<p>For the MS-PCR analysis, separate reactions were carried out to assess both M (methylated) and U (unmethylated) components. In each case, a 20 &#x3bc;L PCR mixture was prepared, comprising 1 &#x3bc;L of bisulfite-converted DNA, 1 &#x3bc;L of each forward and reverse primer (100 pmoL) specific to either the methylated or unmethylated sequences (separate for each reaction), 8 &#x3bc;L of ZymoTaq master mix, and 9 &#x3bc;L of nuclease-free water. The PCR cycle consisted of an initial denaturation at 95&#xb0;C for 10 minutes, followed by 35 cycles, each involving denaturation at 95&#xb0;C for 30 seconds, annealing at 57&#xb0;C for 35 seconds, extension at 72&#xb0;C for 30 seconds, and a final extension at 72&#xb0;C for 10 minutes.</p>
</sec>
</sec>
<sec id="s2_3">
<title>Methylation standard DNA preparation</title>
<p>Commercially purchased fully methylated DNA (100% M) and fully unmethylated DNA (100% U) (Qiagen, Germany) were used as positive and negative controls respectively. The standard concentrations of DNA methylation were prepared as follows 0%, 5%, 10%, 25%, 50%, 75%, and 100% by mixing both M and U DNA to prepare a standard curve.</p>
<sec id="s2_3_1">
<title>Agarose gel electrophoresis and quantification</title>
<p>We performed a 1.5% agarose gel electrophoresis to separate the PCR-amplified products obtained using both methylated and unmethylated primers. The standards included samples with 0%, 10%, 25%, 50%, 75%, and 100% methylation levels. The band intensities, representing the presence or absence of M and U MS-PCR products, were visualized using the ImageQuant LAS 500 system (GE Healthcare, UK) and subsequently compared with the control standards. [19].</p>
</sec>
</sec>
<sec id="s2_4">
<title>Gene expression analysis</title>
<sec id="s2_4_1">
<title>RNA extraction, and cDNA synthesis</title>
<p>The total RNA was extracted from whole blood using the TRIzol manual method (Chomczynski and Sacchi 1987). In a 2 mL centrifuge tube, an equal volume of whole blood (500 &#x3bc;L) and TRIzol reagent (500 &#x3bc;L) were combined for total RNA isolation. The resulting RNA pellet was dissolved in 50 &#x3bc;L of Nuclease-free sterile water and stored at -20 &#xb0;C until further use. The purity and concentration of the RNA were evaluated using a NanoDrop 2000 spectrophotometer (ThermoFisher Scientific, MA, USA). To eliminate any residual genomic DNA from the total RNA, RNase-free DNase I (ThermoFisher Scientific, MA, USA) was used following the manufacturer&#x2019;s instructions.</p>
<p>One microgram (1&#xb5;g) of total RNA was used for complementary DNA (cDNA) synthesis by using the RevertAid H Minus First Strand cDNA Synthesis kit (ThermoFisher Scientific, USA) according to the manufacturer&#x2019;s recommendation.</p>
</sec>
<sec id="s2_4_2">
<title>qRT-PCR analysis</title>
<p>We procured gene-specific primers for TLR2, TLR4, IL-1&#x3b2;, TNF-&#x3b1;, IFN-&#x3b3;, IL-6, CXCL-1, IL-10, TGF-&#x3b2;, and FOXP3 from IDT (USA). The total volume for the qRT-PCR reaction consisted of 2 &#x3bc;L of cDNA (diluted at a ratio of 1:30), 10 &#x3bc;L of Takara SYBR master mix (TB Green Premix Ex Taq II Tli RNase H Plus, Takara Bio Inc., Japan), 0.4 &#x3bc;L of gene-specific primers at a concentration of 200 nM, and 7.2 &#x3bc;L of RNase-free water (Clontech Laboratories, Inc, CA, USA). The qRT-PCR was carried out using the CFX96 Real-Time PCR Detection System (Bio-Rad, USA). The following reaction conditions were applied: initial denaturation at 95 &#xb0;C for 30 seconds, followed by 40 cycles of denaturation at 95 &#xb0;C for 5 seconds and annealing/extension at 60 &#xb0;C for 30 seconds. To verify target-specific amplification, a melt-curve analysis was conducted in the range of 60 &#xb0;C to 90 &#xb0;C at a rate of 0.2 &#xb0;C per minute, with fluorescence intensity observed through the CFX96 Real-Time PCR Detection System (Bio-Rad, USA). Each reaction was performed in duplicates at least, and the human acidic ribosomal protein (HuPO) gene served as a housekeeping gene for normalizing the cycle threshold (Ct) values in both the test and control samples. To assess the expression levels of inflammatory genes in both the case and control groups, we employed a comparative Ct method (2-delta Ct). Additional details regarding the primers are provided in <xref ref-type="supplementary-material" rid="SM2"><bold>Supplementary Table S2</bold></xref>.</p>
</sec>
</sec>
<sec id="s2_5">
<title>Quantification of pro- and anti-inflammatory cytokines in neonates</title>
<p>The EliKine&#x2122; (Abbkine) Human IFN-&#x3b3;, TNF-&#x3b1;, IL-10, and TGF-&#x3b2; ELISA kit employs a sandwich ELISA approach to quantify cytokine levels in samples. In this method, plates are pre-coated with specific antibodies for each cytokine. Standards and samples are subsequently pipetted into the wells, allowing the cytokines (IFN-&#x3b3; range 7.8 pg/mL-500 pg/mL, TNF-&#x3b1;, range 7.8 pg/ml-500 pg/ml, IL-10 range 2.35 pg/ml-150 pg/ml, and TGF-&#x3b2; range 15.6 pg/ml-1000 pg/ml) present in the sample to bind to the immobilized antibodies. Following the removal of any unbound substances, a biotin-conjugated antibody, specific to these cytokines (IFN-&#x3b3;, TNF-&#x3b1;, IL-10, and TGF-&#x3b2;), is introduced to the wells. Proprietary EliKine&#x2122; Streptavidin-HRP conjugates are then added to the wells to bind with unbound streptavidin-enzyme reagents. Finally, a substrate solution is added to the wells, and the color developed is directly proportional to the amount of these cytokines initially bound. The intensity of the color is subsequently measured for quantification.</p>
</sec>
<sec id="s2_6">
<title>Statistical analysis</title>
<p>Shapiro-Wilk test was used to assess the normality distribution. Categorical data were expressed as numbers and percentages. Results of all parameters were presented as median with Interquartile range (IQR). Mann-Whitney U test was used to compare the expression levels of inflammatory genes, and DNA methylation level between the groups. Wilcoxon matched-pairs signed-rank test was used to compare between the follow-up groups. All statistical analyzes were carried out in SPSS 17 (SPSS, Chicago, IL), GraphPad Prism 6.0 (GraphPad Software Inc., CA), and MS-Excel at a 95% confidence interval with <italic>p</italic> &lt; 0.05 was considered as significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<p>The study included 42 neonates with culture-proven late-onset sepsis (LOS), along with an equal number of healthy controls. Follow-up assessments were conducted in 25 of the 42 cases. Both groups exhibited similar baseline characteristics, as shown in <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>. Based on the blood culture report, most of the organisms are identified as gram-negative bacteria. Blood culture analysis showed <italic>K. pneumonia</italic> in 31%, <italic>Elizabethkingia</italic> sp. in 29%, <italic>A. baumannii</italic> in 14%, <italic>Enterobacter</italic> sp. in 9.5%, <italic>Citrobacter</italic> sp. in 4.7%, <italic>E. coli</italic> in 2.4%, <italic>Methicillin-Resistant Staphylococcus aureus</italic> in 4.7%, and <italic>P. aeruginosa</italic> in 4.7%. Of them, 14% cases showed combined bacterial infections like <italic>Enterobacter</italic> sp<italic>, Citrobacter</italic> sp<italic>, A. baumannii</italic>, and <italic>P. aeruginosa</italic> and 12 (28.5%) cases had a recurrent infection. Increased <italic>Elizabethkingia</italic> sp. isolated in our study was due to a nosocomial outbreak during the study period. The hematological investigation of 42 neonates with culture-proven late-onset sepsis (LOS), showed Leukopenia in 10 cases and Leukocytosis in 18 cases.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Baseline characteristics of cases and controls.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">S. No</th>
<th valign="middle" align="left">Characteristics</th>
<th valign="middle" align="left">Cases n = 42 Frequency (%)</th>
<th valign="middle" align="left">Controls n = 42 Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" rowspan="3" align="center">1.</td>
<td valign="middle" align="left">Gender</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
</tr>
<tr>
<td valign="middle" align="left">Male</td>
<td valign="middle" align="center">24 (57%)</td>
<td valign="middle" align="center">23 (55%)</td>
</tr>
<tr>
<td valign="middle" align="left">Female</td>
<td valign="middle" align="center">18 (43%)</td>
<td valign="middle" align="center">19 (45%)</td>
</tr>
<tr>
<td valign="middle" rowspan="3" align="center">2.</td>
<td valign="middle" align="left">Mode of Delivery</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
</tr>
<tr>
<td valign="middle" align="left">SVD</td>
<td valign="middle" align="center">31 (73%)</td>
<td valign="middle" align="center">35 (83%)</td>
</tr>
<tr>
<td valign="middle" align="left">LSCS</td>
<td valign="middle" align="center">11 (27%)</td>
<td valign="middle" align="center">7 (17%)</td>
</tr>
<tr>
<td valign="middle" rowspan="3" align="center">3.</td>
<td valign="middle" align="left">Gestational Age</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
</tr>
<tr>
<td valign="middle" align="left">Term (&gt;37 weeks)</td>
<td valign="middle" align="center">16 (38%)</td>
<td valign="middle" align="center">22 (53%)</td>
</tr>
<tr>
<td valign="middle" align="left">Preterm (30&#x2013;36 weeks)</td>
<td valign="middle" align="center">26 (62%)</td>
<td valign="middle" align="center">20 (47%)</td>
</tr>
<tr>
<td valign="middle" rowspan="3" align="center">4.</td>
<td valign="middle" align="left">Birth Weight</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
</tr>
<tr>
<td valign="middle" align="left">Low birth weight 1500 - 2500 (gms)</td>
<td valign="middle" align="center">24 (57%)</td>
<td valign="middle" align="center">20 (47%)</td>
</tr>
<tr>
<td valign="middle" align="left">Normal birth weight &gt;2500 (gms)</td>
<td valign="middle" align="center">18 (43%)</td>
<td valign="middle" align="center">22 (53%)</td>
</tr>
<tr>
<td valign="middle" rowspan="3" align="center">5.</td>
<td valign="middle" align="left">Liquor</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
</tr>
<tr>
<td valign="middle" align="left">Clear</td>
<td valign="middle" align="center">30 (72%)</td>
<td valign="middle" align="center">32 (76%)</td>
</tr>
<tr>
<td valign="middle" align="left">MSL</td>
<td valign="middle" align="center">12 (28%)</td>
<td valign="middle" align="center">10 (24%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The baseline characteristics are represented in frequency (%); n &#x2013; Numbers; % - Percentage; gms &#x2013; Grams; SVD &#x2013; Spontaneous vaginal delivery, LSCS - Lower segment caesarean section; MSL - Meconium-stained liquor; LBW &#x2013; Low birth weight; NBW &#x2013; Normal birth weight.</p></fn>
</table-wrap-foot>
</table-wrap>
<sec id="s3_1">
<title>Gene-specific DNA methylation patterns of pro- and anti-inflammatory genes</title>
<p><xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref> presents the comparison of DNA methylation levels for pro- and anti-inflammatory genes among culture-positive sepsis, clinical sepsis, and controls, with results expressed as Median with IQR. The selected candidate genes displayed a significant difference in DNA methylation levels between the groups (p&lt;0.0001). Notably, TLR-2 (p=0.9), TGF-&#x3b2; (p=0.1), and FOXP3 (p=0.2) did not exhibit&#xa0;significant differences between culture-positive and clinical&#xa0;sepsis. However, TGF-&#x3b2; and FOXP3 exhibited a hypermethylation pattern in culture-positive and clinical sepsis compared to controls (p&lt;0.0001). A significant difference was observed in DNA methylation levels between clinical sepsis and controls, as well as between the three groups. Overall, there was a trend of hypomethylation in pro-inflammatory genes and hypermethylation in anti-inflammatory genes, except for the IL-10 gene, which displayed hypomethylation in culture-positive and clinical sepsis compared to the control group. <xref ref-type="supplementary-material" rid="SF1"><bold>Supplementary Figure S1</bold></xref> provides a representative agarose gel image illustrating the percentage of DNA methylation in pro- and anti-inflammatory cytokine genes among the neonates with late-onset neonatal sepsis (LONS) and healthy controls enrolled in this study.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>mRNA levels of pro-inflammatory cytokines from culture-positive, clinical sepsis, and healthy controls.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Gene</th>
<th valign="middle" align="center">Culture + sepsis (A)</th>
<th valign="middle" align="center">Clinical sepsis (B)</th>
<th valign="middle" align="center"><italic>p</italic> value (A vs B)</th>
<th valign="middle" align="center">Controls (C)</th>
<th valign="middle" align="center"><italic>p</italic> value (A vs C)</th>
<th valign="middle" align="center"><italic>p</italic> value (B vs C)</th>
<th valign="middle" align="center"><italic>p</italic> value (Kruskal-Wallis)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center"><italic>TLR-2</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.9</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">75</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">50-75</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>TLR-4</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">62.5</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">25-50</td>
<td valign="middle" align="center">50-75</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>TNF-&#x3b1;</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">50</td>
<td valign="middle" align="center">50</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">25-50</td>
<td valign="middle" align="center">50-75</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>IFN-&#x3b3;</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">50</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">25-50</td>
<td valign="middle" align="center">50-75</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>IL-1&#x3b2;</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">50</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">25-50</td>
<td valign="middle" align="center">50-75</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>IL-6</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.004</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">75</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">50-75</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>CXCL1</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">50</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">25-50</td>
<td valign="middle" align="center">50-75</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>IL-10</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">0.001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">50</td>
<td valign="middle" align="center">75</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">10-25</td>
<td valign="middle" align="center">50-75</td>
<td valign="middle" align="center">50-75</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>TGF-&#x3b2;</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.1</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">75</td>
<td valign="middle" align="center">75</td>
<td valign="middle" align="center">25</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">50-75</td>
<td valign="middle" align="center">75-75</td>
<td valign="middle" align="center">25-25</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>FOXP3</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.2</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.02</td>
<td valign="middle" rowspan="3" align="center">0.004</td>
<td valign="middle" rowspan="3" align="center">0.007</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">75</td>
<td valign="middle" align="center">75</td>
<td valign="middle" align="center">50</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">50-75</td>
<td valign="middle" align="center">75-75</td>
<td valign="middle" align="center">50-75</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Mann Whitney U test was used to compare the gene expression levels between culture + vs clinical sepsis. Kruskal-Wallis test was used to compare the gene expression levels between culture + vs clinical sepsis vs controls. Data are mentioned in median with interquartile range. <italic>p</italic>-value, &lt; 0.05.</p></fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="supplementary-material" rid="SM3"><bold>Supplementary Tables S3A, B</bold></xref> detail the comparison of DNA methylation levels for pro- and anti-inflammatory genes within subgroups, such as gestational age, birth weight, and disease outcome. IL-6 (p=0.04) displayed a significant difference between survivors and non-survivors. Additionally, TGF-&#x3b2; (p=0.02) exhibited a significant difference between pre-term and term groups, with hypermethylation in the pre-term group compared to the term group. However, other genes did not exhibit significant differences in any of the subgroups.</p>
<p>In the follow-up group, aside from TLR-4 (p=0.08), CXCL1 (p=0.9), and IL-10 (p=0.7), all other genes showed significant differences. Specifically, hypermethylation in pro-inflammatory genes and hypomethylation in anti-inflammatory genes were observed in pre-treatment group compared to post-treatment group (<xref ref-type="table" rid="T3"><bold>Table&#xa0;3</bold></xref>). Notably, the differences were less pronounced in TLR-4 (p=0.002), TNF-&#x3b1; (p=0.01), and IFN-&#x3b3; (p=0.009) compared to TLR-2, IL-1&#x3b2;, TGF-&#x3b2;, and FOXP3 (p&lt;0.0001), which exhibited greater disparities between the groups.</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Comparison of inflammatory gene expression in follow-up cases.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="center">Group</th>
<th valign="middle" rowspan="2" align="center">No</th>
<th valign="middle" colspan="10" align="center">% Methylation (median, IQR)</th>
</tr>
<tr>
<th valign="middle" align="center"><italic>TLR2</italic></th>
<th valign="middle" align="center"><italic>TLR4</italic></th>
<th valign="middle" align="center"><italic>TNF-&#x3b1;</italic></th>
<th valign="middle" align="center"><italic>IFN-&#x3b3;</italic></th>
<th valign="middle" align="center"><italic>IL-1&#x3b2;</italic></th>
<th valign="middle" align="center"><italic>IL-6</italic></th>
<th valign="middle" align="center"><italic>CXCL1</italic></th>
<th valign="middle" align="center"><italic>IL-10</italic></th>
<th valign="middle" align="center"><italic>TGF-&#x3b2;</italic></th>
<th valign="middle" align="center"><italic>FOXP3</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">Pre treatment</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">10 (10-25)</td>
<td valign="middle" align="center">10 (10-21.25)</td>
<td valign="middle" align="center">25 (10-25)</td>
<td valign="middle" align="center">25 (10-25)</td>
<td valign="middle" align="center">10 (10-25)</td>
<td valign="middle" align="center">10 (10-25)</td>
<td valign="middle" align="center">10 (10-25)</td>
<td valign="middle" align="center">25 (10-25)</td>
<td valign="middle" align="center">75 (50-75)</td>
<td valign="middle" align="center">75 (50-75)</td>
</tr>
<tr>
<td valign="middle" align="center">Post treatment</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">50 (25-50)</td>
<td valign="middle" align="center">17.5 (10-25)</td>
<td valign="middle" align="center">25 (25-50)</td>
<td valign="middle" align="center">25 (25-50)</td>
<td valign="middle" align="center">25 (25-50)</td>
<td valign="middle" align="center">25 (10-50)</td>
<td valign="middle" align="center">10 (10-25)</td>
<td valign="middle" align="center">10 (10-25)</td>
<td valign="middle" align="center">25 (25-50)</td>
<td valign="middle" align="center">25 (10-25)</td>
</tr>
<tr>
<td valign="middle" colspan="2" align="center"><italic>P</italic> value</td>
<td valign="middle" align="center">&lt;0.0001</td>
<td valign="middle" align="center">0.08</td>
<td valign="middle" align="center">0.01</td>
<td valign="middle" align="center">0.009</td>
<td valign="middle" align="center">&lt;0.0001</td>
<td valign="middle" align="center">0.002</td>
<td valign="middle" align="center">0.9</td>
<td valign="middle" align="center">0.7</td>
<td valign="middle" align="center">&lt;0.0001</td>
<td valign="middle" align="center">&lt;0.0001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Mann Whitney U test was used to compare the gene expression levels of inflammatory genes between pre-treatment and post treatment group. Data are mentioned in median with interquartile range. <italic>p</italic>-value, &lt; 0.05.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_2">
<title>Expression profile of candidate pro- and anti-inflammatory genes</title>
<p>In compliance with the inclusion and exclusion criteria, we included a total of forty-two neonates with late-onset sepsis (57% males, 43% females) and forty-two healthy control (HC) neonates, matched for gestational age and gender (55% males, 45% females). We also included twenty-three neonates with clinical sepsis, despite negative blood cultures. <xref ref-type="table" rid="T4"><bold>Table&#xa0;4</bold></xref> offers a comparison of pro- and anti-inflammatory gene expression among culture-positive sepsis (n=42), clinical sepsis (n=23), and controls (n=42). All genes demonstrated significant differences between the groups (p&lt;0.0001), except for TLR-2 (p=0.2), IFN-&#x3b3; (p=0.2), TGF-&#x3b2; (p=0.4), and FOXP3 (p=0.1), which did not exhibit a significant difference between culture-positive and clinical sepsis. Notably, TGF-&#x3b2;, and FOXP3 expression was lower in culture-positive sepsis compared to clinical sepsis. TGF-&#x3b2; and FOXP3 displayed lower expression in both culture-positive and clinical sepsis compared to controls (p&lt;0.0001). Overall, higher expression of pro-inflammatory genes and lower expression of anti-inflammatory genes were observed in culture-positive and clinical sepsis compared to controls, except for IL-10, which exhibited higher expression than controls.</p>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>Comparison of % DNA methylation levels of pro-inflammatory genes in late-onset neonatal sepsis cases and controls.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Gene</th>
<th valign="middle" align="center">Culture + sepsis (A)</th>
<th valign="middle" align="center">Clinical sepsis (B)</th>
<th valign="middle" align="center"><italic>p</italic> value (A vs B)</th>
<th valign="middle" align="center">Controls (C)</th>
<th valign="middle" align="center"><italic>p</italic> value (A vs C)</th>
<th valign="middle" align="center"><italic>p</italic> value (B vs C)</th>
<th valign="middle" align="center"><italic>p</italic> value (Kruskal-Wallis)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center"><italic>TLR-2</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.2</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">0.0006</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">4.4</td>
<td valign="middle" align="center">3.87</td>
<td valign="middle" align="center">2.7</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">3.4-5.7</td>
<td valign="middle" align="center">2.8-6.1</td>
<td valign="middle" align="center">1.9-3.6</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>TLR-4</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">6.8</td>
<td valign="middle" align="center">3.5</td>
<td valign="middle" align="center">1.9</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">4.3-10.6</td>
<td valign="middle" align="center">2.8-4.5</td>
<td valign="middle" align="center">1.5-2.9</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>TNF-&#x3b1;</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.004</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">5.47</td>
<td valign="middle" align="center">4.4</td>
<td valign="middle" align="center">1.95</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">4.4-7.5</td>
<td valign="middle" align="center">3.0-5.6</td>
<td valign="middle" align="center">1.7-3.1</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>IFN-&#x3b3;</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.2</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">0.0008</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">6.73</td>
<td valign="middle" align="center">6.09</td>
<td valign="middle" align="center">4.42</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">4.9-9.3</td>
<td valign="middle" align="center">3.8-8.4</td>
<td valign="middle" align="center">3.4-5.0</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>IL-1&#x3b2;</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.01</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">0.003</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">5.71</td>
<td valign="middle" align="center">3.8</td>
<td valign="middle" align="center">1.98</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">4.2-7.8</td>
<td valign="middle" align="center">1.7-6.9</td>
<td valign="middle" align="center">1.3-2.7</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>IL-6</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.001</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">8.14</td>
<td valign="middle" align="center">5.6</td>
<td valign="middle" align="center">3.05</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">5.7-11.8</td>
<td valign="middle" align="center">3.5-8.2</td>
<td valign="middle" align="center">2.4-4.2</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>CXCL1</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">0.0002</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">5.41</td>
<td valign="middle" align="center">2.7</td>
<td valign="middle" align="center">1.68</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">3.8-6.9</td>
<td valign="middle" align="center">1.9-3.4</td>
<td valign="middle" align="center">1.3-2.3</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>IL-10</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.02</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">4</td>
<td valign="middle" align="center">2.9</td>
<td valign="middle" align="center">1.9</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">2.7-5.4</td>
<td valign="middle" align="center">2.5-3.6</td>
<td valign="middle" align="center">1.5-2.5</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>TGF-&#x3b2;</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.4</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">1.9</td>
<td valign="middle" align="center">2.2</td>
<td valign="middle" align="center">4.2</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">1.4-2.6</td>
<td valign="middle" align="center">1.3-2.6</td>
<td valign="middle" align="center">3.7-4.6</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>FOXP3</italic></td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">0.1</td>
<td valign="middle" align="center"/>
<td valign="middle" rowspan="3" align="center">&lt;0.0001</td>
<td valign="middle" rowspan="3" align="center">0.03</td>
<td valign="middle" rowspan="3" align="center">0.0005</td>
</tr>
<tr>
<td valign="middle" align="center">Median</td>
<td valign="middle" align="center">1.8</td>
<td valign="middle" align="center">2.6</td>
<td valign="middle" align="center">2.9</td>
</tr>
<tr>
<td valign="middle" align="center">IQR</td>
<td valign="middle" align="center">1.3-2.8</td>
<td valign="middle" align="center">1.5-2.9</td>
<td valign="middle" align="center">2.1-3.8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Mann Whitney U test was used to compare the % DNA methylation level between culture + vs clinical sepsis. Kruskal-Wallis test was used to compare the % DNA methylation level between culture + vs clinical sepsis vs controls. Data are mentioned in median with interquartile range. <italic>p</italic>-value, &lt; 0.05.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Further, an analysis of the expression levels of pro- and anti-inflammatory cytokines within sub-groups based on gestational age, birth weight, and disease outcome (<xref ref-type="supplementary-material" rid="SM4"><bold>Supplementary Tables S4A, B</bold></xref>) were performed. IFN-&#x3b3; (p=0.05) and IL-6 (p=0.01) showed a significant difference between survivors and non-survivors, with higher expression levels in the non-survivor group. A significantly lower expression of TGF-&#x3b2; (p=0.03) was observed in the preterm group compared to the term group, while other genes did not display significant expression differences.</p>
<p><xref ref-type="table" rid="T5"><bold>Table&#xa0;5</bold></xref> present the expression of pro- and anti-inflammatory genes in the follow-up group of culture-positive sepsis, comparing pre-treatment (under 12 hours) and post-treatment (72 hours) with standard antibiotic therapy. TLR-4 (p=0.2), and CXCL1 (p=0.6) did not show significant differences during the follow-up, while other genes exhibited significant differences. Pro-inflammatory genes displayed lower expression in the post-treatment group compared to the pre-treatment group, whereas anti-inflammatory gene expression was higher in the post-treatment group. Notably, IL-10 expression was further elevated in the post-treatment group.</p>
<table-wrap id="T5" position="float">
<label>Table&#xa0;5</label>
<caption>
<p>Comparison of % DNA methylation of inflammatory genes in follow-up cases.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="center">Group</th>
<th valign="middle" rowspan="2" align="center">No</th>
<th valign="middle" colspan="11" align="center">Gene expression, median (IQR)</th>
</tr>
<tr>
<th valign="middle" align="center"><italic>TLR2</italic></th>
<th valign="middle" align="center"><italic>TLR4</italic></th>
<th valign="middle" align="center"><italic>NF&#x3ba;B</italic></th>
<th valign="middle" align="center"><italic>TNF-&#x3b1;</italic></th>
<th valign="middle" align="center"><italic>IFN-&#x3b3;</italic></th>
<th valign="middle" align="center"><italic>IL-1&#x3b2;</italic></th>
<th valign="middle" align="center"><italic>IL-6</italic></th>
<th valign="middle" align="center"><italic>CXCL1</italic></th>
<th valign="middle" align="center"><italic>IL-10</italic></th>
<th valign="middle" align="center"><italic>TGF-&#x3b2;</italic></th>
<th valign="middle" align="center"><italic>FOXP3</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">Pre treatment</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">4.6 (4.2-6.0)</td>
<td valign="middle" align="center">7.1 (4.9-10.7)</td>
<td valign="middle" align="center">5.1 (3.2-8.1)</td>
<td valign="middle" align="center">5.1 (3.9-6.9)</td>
<td valign="middle" align="center">7.9 (5.3-9.3)</td>
<td valign="middle" align="center">6.5 (4.1-8.8)</td>
<td valign="middle" align="center">7.4 (4.6-10.6)</td>
<td valign="middle" align="center">5.0 (3.3-6.5)</td>
<td valign="middle" align="center">3.8 (2.7-6.3)</td>
<td valign="middle" align="center">1.6 (1.3-2.2)</td>
<td valign="middle" align="center">1.8 (1.0-3.0)</td>
</tr>
<tr>
<td valign="middle" align="center">Post treatment</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">3.7 (2.6-4.2)</td>
<td valign="middle" align="center">6.5 (5.0-8.0)</td>
<td valign="middle" align="center">5.1 (4.2-6.6)</td>
<td valign="middle" align="center">3.7 (2.5-5.0)</td>
<td valign="middle" align="center">5.4 (4.1-6.9)</td>
<td valign="middle" align="center">3.5 (2.5-6.2)</td>
<td valign="middle" align="center">4.6 (2.5-6.5)</td>
<td valign="middle" align="center">4.8 (4.2-6.2)</td>
<td valign="middle" align="center">5.4 (4.2-6.6)</td>
<td valign="middle" align="center">7.7 (5.9-7.7)</td>
<td valign="middle" align="center">4.19 (3.3-5.6)</td>
</tr>
<tr>
<td valign="middle" colspan="2" align="center"><italic>p</italic> value</td>
<td valign="middle" align="center">0.0005</td>
<td valign="middle" align="center">0.2</td>
<td valign="middle" align="center">0.7</td>
<td valign="middle" align="center">0.005</td>
<td valign="middle" align="center">0.007</td>
<td valign="middle" align="center">0.003</td>
<td valign="middle" align="center">0.003</td>
<td valign="middle" align="center">0.6</td>
<td valign="middle" align="center">0.04</td>
<td valign="middle" align="center">&lt;0.0001</td>
<td valign="middle" align="center">&lt;0.0001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Mann Whitney U test was used to compare the % DNA methylation levels of inflammatory genes between pre-treatment and post treatment group. Data are mentioned in median with interquartile range. <italic>p</italic>-value, &lt; 0.05.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_3">
<title>Plasma levels of pro- and anti-inflammatory cytokines in neonates with LONS and controls</title>
<p><xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref> illustrates the plasma levels of selected inflammatory cytokines, including TNF-&#x3b1;, IFN-&#x3b3;, IL-10, and TGF-&#x3b2;, in culture-positive sepsis (n=42) and healthy controls (n=42). A significant difference was observed between the two groups, with higher levels of TNF-&#x3b1;, IFN-&#x3b3;, and IL-10, and lower levels of TGF-&#x3b2; in culture-positive sepsis compared to controls. These findings align with the gene expression and methylation results in our study. In the follow-up, the analysis between pre and post treatment (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>), TNF-&#x3b1; and IFN-&#x3b3; levels were reduced, and TGF-&#x3b2; levels increased in culture-positive sepsis compared to controls. However, no significant difference was observed in IL-10 levels. ROC analysis demonstrated that TNF-&#x3b1;, IFN-&#x3b3;, IL-10, and TGF-&#x3b2; could serve as effective diagnostic criteria for distinguishing culture-positive sepsis from healthy controls (<xref ref-type="supplementary-material" rid="SM5"><bold>Supplementary Table S5</bold></xref>). <xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref> depicts the ROC analysis of pro- and anti-inflammatory cytokine levels. All cytokines, except for TGF-&#x3b2;, exhibited significantly higher levels in cases than in controls (p&lt;0.0001).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Cytokine levels in plasma of neonates with late-onset neonatal sepsis (LONS) and controls, including follow-up data.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1613333-g001.tif">
<alt-text content-type="machine-generated">The image shows two rows of box plots comparing cytokine levels. The top row compares cases and controls for IFN-&#x3b3;, TNF-&#x3b1;, IL-10, and TGF-&#x3b2; with significant differences marked by asterisks. The bottom row compares pre-treatment and post-treatment cytokine levels for the same markers, also showing significant changes marked by asterisks. Each plot uses different colors for distinction.</alt-text>
</graphic></fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>ROC analysis of inflammatory cytokines. Diagnostic performance of plasma cytokines IFN-&#x3b3;, TNF-&#x3b1;, IL-10 and TGF-&#x3b2; in differentiating cases and controls group; AUC, Area under the curve; <italic>p</italic>-value, &lt;0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1613333-g002.tif">
<alt-text content-type="machine-generated">Four ROC curves are displayed for IFN-&#x3b3;, TNF-&#x3b1;, IL-10, and TGF-&#x3b2;. Each chart shows sensitivity versus 1-specificity, with a diagonal reference line. TNF-&#x3b1; and TGF-&#x3b2; curves demonstrate better diagnostic performance, deviating from the diagonal.</alt-text>
</graphic></fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>This study provides comprehensive insights into the molecular and immunological landscape of late-onset sepsis (LOS) in neonates, emphasizing the interplay between gene-specific DNA methylation, gene expression, and cytokine profiles. The findings demonstrate a distinct pattern of immune dysregulation in culture-positive sepsis compared to healthy controls and clinical sepsis, reinforcing the role of epigenetic regulation in the pathophysiology of neonatal sepsis.</p>
<sec id="s4_1">
<title>Microbial profile and nosocomial influence</title>
<p>Blood culture analysis identified a predominance of gram-negative bacteria, with <italic>Klebsiella pneumoniae</italic> (31%) and <italic>Elizabethkingia</italic> sp. (29%) being the most common pathogens. The increased prevalence of <italic>Elizabethkingia</italic> sp. was attributed to a nosocomial outbreak during the study period (<xref ref-type="bibr" rid="B2">2</xref>). The diversity of pathogens, including <italic>Acinetobacter baumannii</italic>, <italic>Enterobacter</italic> sp., and <italic>Pseudomonas aeruginosa</italic>, along with combined infections in 14% of cases, underscores the complexity of microbial etiology in neonatal sepsis. The high recurrence rate (28.5%) highlights the challenge of eradicating pathogens in nosocomial settings and the need for stringent infection control measures.</p>
</sec>
<sec id="s4_2">
<title>DNA methylation profiles and epigenetic modulation</title>
<p>DNA methylation analysis revealed significant differences in the methylation patterns of pro- and anti-inflammatory genes between culture-positive sepsis, clinical sepsis, and controls. A notable trend of hypomethylation in pro-inflammatory genes (e.g., TLR-2, TLR-4, IL-1&#x3b2;) and hypermethylation in anti-inflammatory genes (e.g., TGF-&#x3b2;, FOXP3) was observed in sepsis groups compared to controls. An experimental study by Gazzer et&#xa0;al. (2010) demonstrated that the TNF promoter was methylated and transcriptionally inactive in resting monocytes. However, during exposure to endotoxins, rapid demethylation occurred at the promoter region, exposing the transcription binding site for NF&#x3ba;B. As it progressed to endotoxin tolerance, rapid methylation of TNF promoters occurred due to the recruitment of DNMTs (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). Interestingly, IL-10 exhibited hypomethylation in both culture-positive and clinical sepsis, suggesting a persistent pro-inflammatory state despite its immunomodulatory role. A study by Lorente-Pozo et&#xa0;al. (2021) showed hypomethylation of IL-10, IL-6, and IL-8 using a DNA methylation array in early and late-onset neonatal sepsis, supporting our findings (<xref ref-type="bibr" rid="B22">22</xref>). Lorente-Sorolla et&#xa0;al. (2019) demonstrated increased expression of IL-10 and IL-6 genes in adult septic patients with organ dysfunction and associated these changes with altered DNA methylation in monocytes (<xref ref-type="bibr" rid="B23">23</xref>). TLR-2, TGF-&#x3b2;, and FOXP3 did not exhibit significant differences between culture-positive and clinical sepsis, indicating shared epigenetic patterns between these groups. Subgroup analysis showed that IL-6 and TGF-&#x3b2; methylation levels varied significantly between survivors and non-survivors and between preterm and term neonates, respectively, highlighting the potential prognostic value of DNA methylation signatures.</p>
</sec>
<sec id="s4_3">
<title>Gene expression patterns in culture-positive and clinical sepsis</title>
<p>The expression profiles of candidate pro- and anti-inflammatory genes further validated the methylation findings. Higher expression of pro-inflammatory genes (e.g., TLR-4, TNF-&#x3b1;, IL-1&#x3b2;, IFN-&#x3b3;) and reduced expression of anti-inflammatory genes (e.g., TGF-&#x3b2;, FOXP3) were observed in both culture-positive and clinical sepsis groups compared to controls. Based on other studies, the infection may trigger the initiation of innate immune responses in neonates through the TLR-2 and TLR-4 signaling pathways, subsequently activating the transcription factor NF&#x3ba;B (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). Macrophages and monocytes play a pivotal role in releasing pro-inflammatory cytokines such as IL-1&#x3b2;, TNF-&#x3b1;, and IL-6 (<xref ref-type="bibr" rid="B26">26</xref>), which exhibit higher expression in cases of culture-positive sepsis. The elevated expression of IFN-&#x3b3; in our study may play a role in activating macrophages and monocytes in response to infection during sepsis (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>). Furthermore, CXCL1 has the role in recruiting neutrophils to control infection and promotes the release of pro-inflammatory cytokines as cited by previous study (<xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B32">32</xref>). The increased expression of CXCL1 in our study indicates an increase in pro-inflammatory genes, consistent with the elevated leukocyte count observed in 64% of cases compared to controls. Notably, TGF-&#x3b2; and FOXP3 expression was lower in culture-positive sepsis cases than in clinical sepsis, suggesting a more pronounced suppression of regulatory pathways in culture-positive cases. IL-10, despite its anti-inflammatory role, exhibited higher expression in sepsis groups, likely reflecting a compensatory mechanism aimed at dampening excessive inflammation. Expression analysis in subgroups revealed significant differences in IFN-&#x3b3; and IL-6 between survivors and non-survivors, with higher expression correlating with poor outcomes. Similarly, TGF-&#x3b2; expression was significantly lower in preterm neonates compared to term neonates, suggesting a compromised anti-inflammatory response in the preterm group. A recent study by Sherrianne et&#xa0;al. (2020) also revealed upregulation of TLR-2, TLR-4, IFN-&#x3b3;, IL-6, IL-1&#x3b2;, and IL-10 expression in neonatal sepsis (<xref ref-type="bibr" rid="B33">33</xref>).</p>
</sec>
<sec id="s4_4">
<title>Plasma cytokine profiles and diagnostic utility</title>
<p>Cytokine analysis corroborated the molecular findings, with significantly higher plasma levels of TNF-&#x3b1;, IFN-&#x3b3;, and IL-10 and lower levels of TGF-&#x3b2; in culture-positive sepsis compared to controls. Post-treatment, TNF-&#x3b1; and IFN-&#x3b3; levels decreased, and TGF-&#x3b2; levels increased, indicating a shift towards immune resolution. However, IL-10 levels did not show significant differences between pre- and post-treatment, reinforcing its sustained role in modulating immune responses during and after infection. T regulatory cells are involved in the secretion of IL-10 and TGF-&#x3b2; cytokines during inflammatory conditions. Previous studies have associated increased levels of TNF-&#x3b1;, IL-6, and IL-8 with severe sepsis and shock (<xref ref-type="bibr" rid="B34">34</xref>&#x2013;<xref ref-type="bibr" rid="B38">38</xref>). In a neonatal mouse model of sepsis, the administration of IFN-&#x3b3; at 18 hours resulted in improved survival and reduced bacterial counts in group B streptococcal infection, partially reversing the host&#x2019;s defense against bacteria (<xref ref-type="bibr" rid="B39">39</xref>). Tissi&#xe8;res et&#xa0;al. (2012) reported the reversal of immune response deficiency to bacteria in neonates with ex-vivo treatment of IFN-&#x3b3;, which led to increased levels of IL-6 and TNF-&#x3b1; and decreased IL-10 levels (<xref ref-type="bibr" rid="B40">40</xref>). ROC analysis demonstrated that TNF-&#x3b1;, IFN-&#x3b3;, IL-10, and TGF-&#x3b2; could serve as effective biomarkers for distinguishing culture-positive sepsis from healthy controls, with high sensitivity and specificity. ROC curves further highlighted the diagnostic value of these cytokines, with all markers except TGF-&#x3b2; exhibiting significantly higher levels in sepsis cases (p&lt;0.0001).</p>
</sec>
<sec id="s4_5">
<title>Impact of antibiotic treatment on methylation and gene expression</title>
<p>The follow-up analysis revealed significant differences in DNA methylation and gene expression levels pre- and post-treatment. Following antibiotic therapy, a shift towards hypermethylation in pro-inflammatory genes and hypomethylation in anti-inflammatory genes was observed, indicative of a resolution of the inflammatory response. The cytokine IL-6, extensively researched in neonatal sepsis for its short half-life, showed a significant decrease within 48 hours of treatment (<xref ref-type="bibr" rid="B41">41</xref>&#x2013;<xref ref-type="bibr" rid="B44">44</xref>). Our study supports this finding, demonstrating a marked reduction in IL-6 expression in the post-treatment group. Notably, IL-10 expression remained elevated post-treatment, suggesting its sustained role in immune regulation during recovery. The increased expression of IL-10 in our study, secreted by various immune cells such as T cells, monocytes, macrophages, and NK cells (<xref ref-type="bibr" rid="B45">45</xref>), plays a complex role in neonatal sepsis. In adult sepsis, higher levels of IL-10 are associated with poor prognosis and septic shock. While IL-10 has a protective role in sepsis by suppressing pro-inflammatory cytokines, a high ratio of IL-10 to TNF-&#x3b1; has been linked to severe late-onset sepsis (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). Our study indicated an increased expression of IL-10, along with lower expression of pro-inflammatory genes in the pre-treatment group (<xref ref-type="bibr" rid="B47">47</xref>&#x2013;<xref ref-type="bibr" rid="B49">49</xref>). In the follow-up after 72 hours, there was an increase in IL-10, TGF-&#x3b2;, and FOXP3 expression, suggesting that immune suppression occurs in the later stages of sepsis.</p>
<p>The observed changes in gene expression align with the plasma cytokine levels, where TNF-&#x3b1; and IFN-&#x3b3; decreased post-treatment, while TGF-&#x3b2; increased. These findings reinforce the dynamic nature of immune regulation during neonatal sepsis and recovery, emphasizing the potential role of epigenetic modifications as biomarkers for disease progression and treatment response.</p>
</sec>
<sec id="s4_6">
<title>Clinical implications and future directions</title>
<p>The observed trends in DNA methylation, gene expression, and cytokine levels provide valuable insights into the immunopathogenesis of late onset neonatal sepsis. The interplay between pro- and anti-inflammatory responses, regulated through epigenetic modifications, highlights potential targets for early diagnosis and therapeutic intervention. The persistent elevation of IL-10 and the differential expression of key inflammatory mediators suggest that modulation of immune responses may be a promising strategy for improving outcomes in neonatal sepsis. Future research should explore the mechanistic underpinnings of these findings, particularly the role of DNA methylation in driving long-term immune dysregulation and its potential as a biomarker for sepsis prognosis and treatment response.</p>
</sec>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>This study underscores the role of DNA methylation in modulating inflammatory responses in neonates with LOS. The observed hypomethylation of pro-inflammatory genes and hypermethylation of anti-inflammatory genes suggest an epigenetic basis for the exaggerated inflammatory response in neonatal sepsis. The reversibility of these changes with treatment further highlights the potential of epigenetic modifications as both biomarkers and therapeutic targets in neonatal sepsis management. Further research is warranted to explore the clinical utility of these findings in improving neonatal sepsis outcomes.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The data generated in this study consist of quantitative real-time PCR (qRT-PCR) and ELISA measurements. No large-scale sequencing, omics, or imaging datasets requiring deposition in public repositories were generated. All raw and processed qRT-PCR and ELISA data supporting the findings of this study are included within the article and/or its supplementary material and are available from the corresponding author upon reasonable request.</p></sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Jawaharlal Institute of Postgraduate Medical Education and Research. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x2019; legal guardians/next of kin.</p></sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>SS: Writing &#x2013; original draft, Formal analysis, Visualization, Validation, Investigation, Data curation, Conceptualization, Methodology, Writing &#x2013; review &amp; editing. KM: Data curation, Writing &#x2013; review &amp; editing, Validation, Methodology. ZB: Formal analysis, Writing &#x2013; review &amp; editing, Supervision. BA: Supervision, Conceptualization, Funding acquisition, Writing &#x2013; review &amp; editing, Formal analysis, Project administration, Resources.</p></sec>
<ack>
<title>Acknowledgments</title>
<p>The authors sincerely thank all the neonates, their parents, and the healthy neonates for their participation.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<sec id="s13" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1613333/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1613333/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Presentation1.pptx" id="SF1" mimetype="application/vnd.openxmlformats-officedocument.presentationml.presentation"><label>Supplementary Figure&#xa0;1</label>
<caption>
<p>Representative result of MS-PCR analysis &#x2013;inflammatory Cytokine Genes. The Supplementary Figures S1 shows the presence of methylation band in agarose gel electrophoresis.</p>
</caption></supplementary-material>
<supplementary-material xlink:href="Table1.doc" id="SM1" mimetype="application/msword"><label>Supplementary Table&#xa0;1</label>
<caption>
<p>List of qRT-PCR Primers. The Supplementary Table S1 shows the primer details of pro- and anti-inflammatory genes and housekeeping genes.</p>
</caption></supplementary-material>
<supplementary-material xlink:href="Table2.doc" id="SM2" mimetype="application/msword"><label>Supplementary Table&#xa0;2</label>
<caption>
<p>List MS-PCR Primers. The Supplementary Table S2 shows the methylation primer details of pro- and anti-inflammatory genes and housekeeping genes.</p>
</caption></supplementary-material>
<supplementary-material xlink:href="Table3.doc" id="SM3" mimetype="application/msword"><label>Supplementary Table&#xa0;3</label>
<caption>
<p>List Bisulfite Pyrosequencing Primers. The Supplementary Table S2 shows the bisulfite pyrosequencing primer details of pro- and anti-inflammatory genes and housekeeping genes.</p>
</caption></supplementary-material>
<supplementary-material xlink:href="Table4.doc" id="SM4" mimetype="application/msword"><label>Supplementary Table&#xa0;4</label>
<caption>
<p><bold>(A)</bold> Comparison of Pro-Inflammatory Gene Expression in Subgroups. Mann Whitney U test was used to compare the pro-Inflammatory gene expression levels between the subgroups. Data are mentioned in median with interquartile range. <italic>p</italic>-value, &lt; 0.05. LBW &#x2013; Low birth weight; NBW &#x2013; Normal birth weight. <bold>(B)</bold> Comparison of expression of anti-inflammatory genes in subgroups. Mann Whitney U test was used to compare the anti-inflammatory gene expression levels between the subgroups. Data are mentioned in median with interquartile range. <italic>p</italic>-value, &lt; 0.05. LBW &#x2013; Low birth weight; NBW &#x2013; Normal birth weight.</p>
</caption></supplementary-material>
<supplementary-material xlink:href="Table5.doc" id="SM5" mimetype="application/msword"><label>Supplementary Table&#xa0;5</label>
<caption>
<p><bold>(A)</bold> Comparison of % DNA Methylation of Pro-Inflammatory Genes in Subgroups. Mann Whitney U test was used to compare the % DNA methylation level of pro-inflammatory gene between the subgroups. Data are mentioned in median with interquartile range. <italic>p</italic>-value, &lt; 0.05. LBW &#x2013; Low birth weight; NBW &#x2013; Normal birth weight. <bold>(B)</bold> Comparison of % DNA methylation of anti-inflammatory genes in subgroups.</p>
</caption></supplementary-material>
<supplementary-material xlink:href="Table5.doc" id="SM6" mimetype="application/msword"><label>Supplementary Table&#xa0;6</label>
<caption>
<p>ROC Analysis of Inflammatory Cytokines for Neonatal Sepsis Discrimination. AUC, Area under the curve; CI, Confidence Interval 95%; <italic>p</italic>-value, &lt;0.05.</p>
</caption></supplementary-material></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fleischmann-Struzek</surname> <given-names>C</given-names></name>
<name><surname>Goldfarb</surname> <given-names>DM</given-names></name>
<name><surname>Schlattmann</surname> <given-names>P</given-names></name>
<name><surname>Schlapbach</surname> <given-names>LJ</given-names></name>
<name><surname>Reinhart</surname> <given-names>K</given-names></name>
<name><surname>Kissoon</surname> <given-names>N</given-names></name>
</person-group>. 
<article-title>The global burden of paediatric and neonatal sepsis: a systematic review</article-title>. <source>Lancet Respir Med</source>. (<year>2018</year>) <volume>6</volume>:<page-range>223&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2213-2600(18)30063-8</pub-id>, PMID: <pub-id pub-id-type="pmid">29508706</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bethou</surname> <given-names>A</given-names></name>
<name><surname>Bhat</surname> <given-names>BV</given-names></name>
</person-group>. 
<article-title>Neonatal sepsis-newer insights</article-title>. <source>Indian J Pediatr</source>. (<year>2022</year>) <volume>89</volume>:<page-range>267&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12098-021-03852-z</pub-id>, PMID: <pub-id pub-id-type="pmid">34170492</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Molloy</surname> <given-names>EJ</given-names></name>
<name><surname>Wynn</surname> <given-names>JL</given-names></name>
<name><surname>Bliss</surname> <given-names>J</given-names></name>
<name><surname>Koenig</surname> <given-names>JM</given-names></name>
<name><surname>Keij</surname> <given-names>FM</given-names></name>
<name><surname>McGovern</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Neonatal sepsis: need for consensus definition, collaboration and core outcomes</article-title>. <source>Pediatr Res</source>. (<year>2020</year>) <volume>88</volume>:<fpage>2</fpage>&#x2013;<lpage>4</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41390-020-0850-5</pub-id>, PMID: <pub-id pub-id-type="pmid">32193517</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wynn</surname> <given-names>JL</given-names></name>
<name><surname>Wong</surname> <given-names>HR</given-names></name>
<name><surname>Shanley</surname> <given-names>TP</given-names></name>
<name><surname>Bizzarro</surname> <given-names>MJ</given-names></name>
<name><surname>Saiman</surname> <given-names>L</given-names></name>
<name><surname>Polin</surname> <given-names>RA</given-names></name>
</person-group>. 
<article-title>Time for a neonatal-specific consensus definition for sepsis</article-title>. <source>Pediatr Crit Care Med</source>. (<year>2014</year>) <volume>15</volume>:<page-range>523&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/PCC.0000000000000157</pub-id>, PMID: <pub-id pub-id-type="pmid">24751791</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Simonsen</surname> <given-names>KA</given-names></name>
<name><surname>Anderson-Berry</surname> <given-names>AL</given-names></name>
<name><surname>Delair</surname> <given-names>SF</given-names></name>
<name><surname>Davies</surname> <given-names>HD</given-names></name>
</person-group>. 
<article-title>Early-onset neonatal sepsis</article-title>. <source>Clin Microbiol Rev</source>. (<year>2014</year>) <volume>27</volume>:<fpage>21</fpage>&#x2013;<lpage>47</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/CMR.00031-13</pub-id>, PMID: <pub-id pub-id-type="pmid">24396135</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Belachew</surname> <given-names>A</given-names></name>
<name><surname>Tewabe</surname> <given-names>T</given-names></name>
</person-group>. 
<article-title>Neonatal sepsis and its association with birth weight and gestational age among admitted neonates in Ethiopia: systematic review and meta-analysis</article-title>. <source>BMC Pediatr</source>. (<year>2020</year>) <volume>20</volume>:<fpage>55</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12887-020-1949-x</pub-id>, PMID: <pub-id pub-id-type="pmid">32020850</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>El Manouni El Hassani</surname> <given-names>S</given-names></name>
<name><surname>Berkhout</surname> <given-names>DJC</given-names></name>
<name><surname>Niemarkt</surname> <given-names>HJ</given-names></name>
<name><surname>Mann</surname> <given-names>S</given-names></name>
<name><surname>de Boode</surname> <given-names>WP</given-names></name>
<name><surname>Cossey</surname> <given-names>V</given-names></name>
<etal/>
</person-group>. 
<article-title>Risk factors for late-onset sepsis in preterm infants: A multicenter case-control study</article-title>. <source>Neonatology</source>. (<year>2019</year>) <volume>116</volume>:<fpage>42</fpage>&#x2013;<lpage>51</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000497781</pub-id>, PMID: <pub-id pub-id-type="pmid">30947195</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hibbert</surname> <given-names>JE</given-names></name>
<name><surname>Currie</surname> <given-names>A</given-names></name>
<name><surname>Strunk</surname> <given-names>T</given-names></name>
</person-group>. 
<article-title>Sepsis-induced immunosuppression in neonates</article-title>. <source>Front Pediatr</source>. (<year>2018</year>) <volume>6</volume>:<elocation-id>357</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fped.2018.00357</pub-id>, PMID: <pub-id pub-id-type="pmid">30555806</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hotchkiss</surname> <given-names>RS</given-names></name>
<name><surname>Monneret</surname> <given-names>G</given-names></name>
<name><surname>Payen</surname> <given-names>D</given-names></name>
</person-group>. 
<article-title>Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy</article-title>. <source>Nat Rev Immunol</source>. (<year>2013</year>) <volume>13</volume>:<page-range>862&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri3552</pub-id>, PMID: <pub-id pub-id-type="pmid">24232462</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Brady</surname> <given-names>J</given-names></name>
<name><surname>Horie</surname> <given-names>S</given-names></name>
<name><surname>Laffey</surname> <given-names>JG</given-names></name>
</person-group>. 
<article-title>Role of the adaptive immune response in sepsis</article-title>. <source>Intensive Care Med Exp</source>. (<year>2020</year>) <volume>8</volume>:<elocation-id>20</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40635-020-00309-z</pub-id>, PMID: <pub-id pub-id-type="pmid">33336293</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Greenfield</surname> <given-names>KG</given-names></name>
<name><surname>Badovinac</surname> <given-names>VP</given-names></name>
<name><surname>Griffith</surname> <given-names>TS</given-names></name>
<name><surname>Knoop</surname> <given-names>KA</given-names></name>
</person-group>. 
<article-title>Sepsis, cytokine storms, and immunopathology: the divide between neonates and adults</article-title>. <source>Immunohorizons</source>. (<year>2021</year>) <volume>5</volume>:<page-range>512&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/immunohorizons.2000104</pub-id>, PMID: <pub-id pub-id-type="pmid">34183380</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bartlett</surname> <given-names>JA</given-names></name>
<name><surname>Fischer</surname> <given-names>AJ</given-names></name>
<name><surname>McCray</surname> <given-names>PBJ</given-names></name>
</person-group>. 
<article-title>Innate immune functions of the airway epithelium</article-title>. <source>Contrib Microbiol</source>. (<year>2008</year>) <volume>15</volume>:<page-range>147&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000136349</pub-id>, PMID: <pub-id pub-id-type="pmid">18511860</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Basha</surname> <given-names>S</given-names></name>
<name><surname>Surendran</surname> <given-names>N</given-names></name>
<name><surname>Pichichero</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Immune responses in neonates</article-title>. <source>Expert Rev Clin Immunol</source>. (<year>2014</year>) <volume>10</volume>:<page-range>1171&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1586/1744666X.2014.942288</pub-id>, PMID: <pub-id pub-id-type="pmid">25088080</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kawai</surname> <given-names>T</given-names></name>
<name><surname>Akira</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors</article-title>. <source>Nat Immunol</source>. (<year>2010</year>) <volume>11</volume>:<page-range>373&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.1863</pub-id>, PMID: <pub-id pub-id-type="pmid">20404851</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>JY</given-names></name>
<name><surname>Liu</surname> <given-names>Y</given-names></name>
<name><surname>Gao</surname> <given-names>XX</given-names></name>
<name><surname>Gao</surname> <given-names>X</given-names></name>
<name><surname>Cai</surname> <given-names>H</given-names></name>
</person-group>. 
<article-title>TLR2 and TLR4 signaling pathways are required for recombinant Brucella abortus BCSP31-induced cytokine production, functional upregulation of mouse macrophages, and the Th1 immune response <italic>in vivo</italic> and in <italic>vitro</italic></article-title>. <source>Cell Mol Immunol</source>. (<year>2014</year>) <volume>11</volume>:<page-range>477&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cmi.2014.28</pub-id>, PMID: <pub-id pub-id-type="pmid">24769793</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Delano</surname> <given-names>MJ</given-names></name>
<name><surname>Ward</surname> <given-names>PA</given-names></name>
</person-group>. 
<article-title>The immune system&#x2019;s role in sepsis progression, resolution, and long-term outcome</article-title>. <source>Immunol Rev</source>. (<year>2016</year>) <volume>274</volume>:<page-range>330&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imr.12499</pub-id>, PMID: <pub-id pub-id-type="pmid">27782333</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Morandini</surname> <given-names>AC</given-names></name>
<name><surname>Santos</surname> <given-names>CF</given-names></name>
<name><surname>Yilmaz</surname> <given-names>&#xd6;</given-names></name>
</person-group>. 
<article-title>Role of epigenetics in modulation of immune response at the junction of host-pathogen interaction and danger molecule signaling</article-title>. <source>Pathog Dis</source>. (<year>2016</year>) <volume>74</volume>:<elocation-id>ftw082</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/femspd/ftw082</pub-id>, PMID: <pub-id pub-id-type="pmid">27542389</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dhas</surname> <given-names>BB</given-names></name>
<name><surname>Antony</surname> <given-names>HA</given-names></name>
<name><surname>Bhat</surname> <given-names>V</given-names></name>
<name><surname>Newton</surname> <given-names>B</given-names></name>
<name><surname>Parija</surname> <given-names>SC</given-names></name>
</person-group>. 
<article-title>Global DNA methylation in neonatal sepsis</article-title>. <source>Indian J Pediatr</source>. (<year>2015</year>) <volume>82</volume>:<page-range>340&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12098-014-1574-5</pub-id>, PMID: <pub-id pub-id-type="pmid">25348460</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Maruthai</surname> <given-names>K</given-names></name>
<name><surname>Sankar</surname> <given-names>S</given-names></name>
<name><surname>Subramanian</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Methylation status of VDR gene and its association with vitamin D status and VDR gene expression in pediatric tuberculosis disease</article-title>. <source>Immunol Invest</source>. (<year>2022</year>) <volume>51</volume>:<fpage>73</fpage>&#x2013;<lpage>87</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/08820139.2020.1810702</pub-id>, PMID: <pub-id pub-id-type="pmid">32847384</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>El Gazzar</surname> <given-names>M</given-names></name>
<name><surname>Liu</surname> <given-names>T</given-names></name>
<name><surname>Yoza</surname> <given-names>BK</given-names></name>
<name><surname>McCall</surname> <given-names>CE</given-names></name>
</person-group>. 
<article-title>Dynamic and selective nucleosome repositioning during endotoxin tolerance</article-title>. <source>J Biol Chem</source>. (<year>2010</year>) <volume>285</volume>:<page-range>1259&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M109.067330</pub-id>, PMID: <pub-id pub-id-type="pmid">19901031</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>El Gazzar</surname> <given-names>M</given-names></name>
<name><surname>Yoza</surname> <given-names>BK</given-names></name>
<name><surname>Chen</surname> <given-names>X</given-names></name>
<name><surname>Hu</surname> <given-names>J</given-names></name>
<name><surname>Hawkins</surname> <given-names>GA</given-names></name>
<name><surname>McCall</surname> <given-names>CE</given-names></name>
</person-group>. 
<article-title>G9a and HP1 couple histone and DNA methylation to TNFalpha transcription silencing during endotoxin tolerance</article-title>. <source>J Biol Chem</source>. (<year>2008</year>) <volume>283</volume>:<page-range>32198&#x2013;208</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M803446200</pub-id>, PMID: <pub-id pub-id-type="pmid">18809684</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lorente-Pozo</surname> <given-names>S</given-names></name>
<name><surname>Navarrete</surname> <given-names>P</given-names></name>
<name><surname>Garz&#xf3;n</surname> <given-names>MJ</given-names></name>
<name><surname>Lara-Cant&#xf3;n</surname> <given-names>I</given-names></name>
<name><surname>Beltr&#xe1;n-Garc&#xed;a</surname> <given-names>J</given-names></name>
<name><surname>Osca-Verdegal</surname> <given-names>R</given-names></name>
<etal/>
</person-group>. 
<article-title>DNA methylation analysis to unravel altered genetic pathways underlying early onset and late onset neonatal sepsis</article-title>. <source>A Pilot Study Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>622599</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.622599</pub-id>, PMID: <pub-id pub-id-type="pmid">33659006</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lorente-Sorolla</surname> <given-names>C</given-names></name>
<name><surname>Garcia-Gomez</surname> <given-names>A</given-names></name>
<name><surname>Catal&#xe0;-Moll</surname> <given-names>F</given-names></name>
<name><surname>Toledano</surname> <given-names>V</given-names></name>
<name><surname>Ciudad</surname> <given-names>L</given-names></name>
<name><surname>Avenda&#xf1;o-Ortiz</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Inflammatory cytokines and organ dysfunction associate with the aberrant DNA methylome of monocytes in sepsis</article-title>. <source>Genome Med</source>. (<year>2019</year>) <volume>11</volume>:<fpage>66</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13073-019-0674-2</pub-id>, PMID: <pub-id pub-id-type="pmid">31665078</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mukherjee</surname> <given-names>S</given-names></name>
<name><surname>Karmakar</surname> <given-names>S</given-names></name>
<name><surname>Babu</surname> <given-names>SP</given-names></name>
</person-group>. 
<article-title>TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review</article-title>. <source>Braz J Infect Dis</source>. (<year>2016</year>) <volume>20</volume>:<fpage>193</fpage>&#x2013;<lpage>204</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bjid.2015.10.011</pub-id>, PMID: <pub-id pub-id-type="pmid">26775799</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kawasaki</surname> <given-names>T</given-names></name>
<name><surname>Kawai</surname> <given-names>T</given-names></name>
</person-group>. 
<article-title>Toll-like receptor signaling pathways</article-title>. <source>Front Immunol</source>. (<year>2014</year>) <volume>5</volume>:<elocation-id>461</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2014.00461</pub-id>, PMID: <pub-id pub-id-type="pmid">25309543</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Arango Duque</surname> <given-names>G</given-names></name>
<name><surname>Descoteaux</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Macrophage cytokines: involvement in immunity and infectious diseases</article-title>. <source>Front Immunol</source>. (<year>2014</year>) <volume>5</volume>:<elocation-id>491</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2014.00491</pub-id>, PMID: <pub-id pub-id-type="pmid">25339958</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Salim</surname> <given-names>T</given-names></name>
<name><surname>Sershen</surname> <given-names>CL</given-names></name>
<name><surname>May</surname> <given-names>EE</given-names></name>
</person-group>. 
<article-title>Investigating the role of TNF-&#x3b1; and IFN-&#x3b3; Activation on the dynamics of iNOS gene expression in LPS stimulated macrophages</article-title>. <source>PloS One</source>. (<year>2016</year>) <volume>11</volume>:<fpage>e0153289</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0153289</pub-id>, PMID: <pub-id pub-id-type="pmid">27276061</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Classen</surname> <given-names>A</given-names></name>
<name><surname>Lloberas</surname> <given-names>J</given-names></name>
<name><surname>Celada</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Macrophage activation: classical versus alternative</article-title>. <source>Methods Mol Biol</source>. (<year>2009</year>) <volume>531</volume>:<fpage>29</fpage>&#x2013;<lpage>43</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-1-59745-396-7_3</pub-id>, PMID: <pub-id pub-id-type="pmid">19347309</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Paudel</surname> <given-names>S</given-names></name>
<name><surname>Baral</surname> <given-names>P</given-names></name>
<name><surname>Ghimire</surname> <given-names>L</given-names></name>
<name><surname>Bergeron</surname> <given-names>S</given-names></name>
<name><surname>Jin</surname> <given-names>L</given-names></name>
<name><surname>DeCorte</surname> <given-names>JA</given-names></name>
<etal/>
</person-group>. 
<article-title>CXCL1 regulates neutrophil homeostasis in pneumonia-derived sepsis caused by <italic>Streptococcus pneumoniae</italic> serotype 3</article-title>. <source>Blood</source>. (<year>2019</year>) <volume>133</volume>:<page-range>1335&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2018-10-878082</pub-id>, PMID: <pub-id pub-id-type="pmid">30723078</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sawant</surname> <given-names>KV</given-names></name>
<name><surname>Poluri</surname> <given-names>KM</given-names></name>
<name><surname>Dutta</surname> <given-names>AK</given-names></name>
<etal/>
</person-group>. 
<article-title>Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions</article-title>. <source>Sci Rep</source>. (<year>2016</year>) <volume>6</volume>:<elocation-id>33123</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep33123</pub-id>, PMID: <pub-id pub-id-type="pmid">27625115</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jin</surname> <given-names>L</given-names></name>
<name><surname>Batra</surname> <given-names>S</given-names></name>
<name><surname>Douda</surname> <given-names>DN</given-names></name>
<name><surname>Palaniyar</surname> <given-names>N</given-names></name>
<name><surname>Jeyaseelan</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>CXCL1 contributes to host defense in polymicrobial sepsis via modulating T cell and neutrophil functions [published correction appears in J Immunol. 2022 Mar 15;208(6):1509. doi: 10.4049/jimmunol.2101213</article-title>. <source>J Immunol</source>. (<year>2014</year>) <volume>193</volume>:<page-range>3549&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1401138</pub-id>, PMID: <pub-id pub-id-type="pmid">25172493</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cai</surname> <given-names>S</given-names></name>
<name><surname>Batra</surname> <given-names>S</given-names></name>
<name><surname>Lira</surname> <given-names>SA</given-names></name>
<name><surname>Kolls</surname> <given-names>JK</given-names></name>
<name><surname>Jeyaseelan</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>CXCL1 regulates pulmonary host defense to Klebsiella Infection via CXCL2, CXCL5, NF-kappaB, and MAPKs</article-title>. <source>J Immunol</source>. (<year>2010</year>) <volume>185</volume>:<page-range>6214&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.0903843</pub-id>, PMID: <pub-id pub-id-type="pmid">20937845</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname> <given-names>S</given-names></name>
<name><surname>Strunk</surname> <given-names>T</given-names></name>
<name><surname>Lee</surname> <given-names>AH</given-names></name>
<name><surname>Gill</surname> <given-names>EE</given-names></name>
<name><surname>Falsafi</surname> <given-names>R</given-names></name>
<name><surname>Woodman</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Whole blood transcriptional responses of very preterm infants during late-onset sepsis</article-title>. <source>PloS One</source>. (<year>2020</year>) <volume>15</volume>:<fpage>e0233841</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0233841</pub-id>, PMID: <pub-id pub-id-type="pmid">32479514</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Martin</surname> <given-names>H</given-names></name>
<name><surname>Olander</surname> <given-names>B</given-names></name>
<name><surname>Norman</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Reactive hyperemia and interleukin 6, interleukin 8, and tumor necrosis factor-alpha in the diagnosis of early-onset neonatal sepsis</article-title>. <source>Pediatrics</source>. (<year>2001</year>) <volume>108</volume>:<fpage>E61</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1542/peds.108.4.e61</pub-id>, PMID: <pub-id pub-id-type="pmid">11581469</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>S&#xe1;ez-Llorens</surname> <given-names>X</given-names></name>
<name><surname>Lagrutta</surname> <given-names>F</given-names></name>
</person-group>. 
<article-title>The acute phase host reaction during bacterial infection and its clinical impact in children</article-title>. <source>Pediatr Infect Dis J</source>. (<year>1993</year>) <volume>12</volume>:<page-range>83&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/00006454-199301000-00017</pub-id>, PMID: <pub-id pub-id-type="pmid">8417431</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kurt</surname> <given-names>AN</given-names></name>
<name><surname>Aygun</surname> <given-names>AD</given-names></name>
<name><surname>Godekmerdan</surname> <given-names>A</given-names></name>
<name><surname>Kurt</surname> <given-names>A</given-names></name>
<name><surname>Dogan</surname> <given-names>Y</given-names></name>
<name><surname>Yilmaz</surname> <given-names>E</given-names></name>
</person-group>. 
<article-title>Serum IL-1beta, IL-6, IL-8, and TNF-alpha levels in early diagnosis and management of neonatal sepsis</article-title>. <source>Mediators Inflamm</source>. (<year>2007</year>) <volume>2007</volume>:<elocation-id>31397</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2007/31397</pub-id>, PMID: <pub-id pub-id-type="pmid">18274637</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Berner</surname> <given-names>R</given-names></name>
<name><surname>Niemeyer</surname> <given-names>C</given-names></name>
<name><surname>Leititis</surname> <given-names>J</given-names></name>
<name><surname>Funke</surname> <given-names>A</given-names></name>
<name><surname>Schwab</surname> <given-names>C</given-names></name>
<name><surname>Rau</surname> <given-names>U</given-names></name>
<etal/>
</person-group>. 
<article-title>Plasma levels and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor-&#x3b1;, interleukin (IL)-1&#x3b2;, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis</article-title>. <source>Pediatr Res</source>. (<year>1998</year>) <volume>44</volume>:<page-range>469&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1203/00006450-199810000-00002</pub-id>, PMID: <pub-id pub-id-type="pmid">9773833</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Caldas</surname> <given-names>JP</given-names></name>
<name><surname>Marba</surname> <given-names>ST</given-names></name>
<name><surname>Blotta</surname> <given-names>MH</given-names></name>
<name><surname>Calil</surname> <given-names>R</given-names></name>
<name><surname>Morais</surname> <given-names>SS</given-names></name>
<name><surname>Oliveira</surname> <given-names>RT</given-names></name>
</person-group>. 
<article-title>Accuracy of white blood cell count, C-reactive protein, interleukin-6 and tumor necrosis factor alpha for diagnosing late neonatal sepsis</article-title>. <source>J Pediatr (Rio J)</source>. (<year>2008</year>) <volume>84</volume>:<page-range>536&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2223/JPED.1838</pub-id>, PMID: <pub-id pub-id-type="pmid">19060982</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cusumano</surname> <given-names>V</given-names></name>
<name><surname>Mancuso</surname> <given-names>G</given-names></name>
<name><surname>Genovese</surname> <given-names>F</given-names></name>
<name><surname>Delfino</surname> <given-names>D</given-names></name>
<name><surname>Beninati</surname> <given-names>C</given-names></name>
<name><surname>Losi</surname> <given-names>E</given-names></name>
<etal/>
</person-group>. 
<article-title>Role of gamma interferon in a neonatal mouse model of group B streptococcal disease</article-title>. <source>Infect Immun</source>. (<year>1996</year>) <volume>64</volume>:<page-range>2941&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/iai.64.8.2941-2944.1996</pub-id>, PMID: <pub-id pub-id-type="pmid">8757817</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tissi&#xe8;res</surname> <given-names>P</given-names></name>
<name><surname>Ochoda</surname> <given-names>A</given-names></name>
<name><surname>Dunn-Siegrist</surname> <given-names>I</given-names></name>
<name><surname>Drifte</surname> <given-names>G</given-names></name>
<name><surname>Morales</surname> <given-names>M</given-names></name>
<name><surname>Pfister</surname> <given-names>R</given-names></name>
<etal/>
</person-group>. 
<article-title>Innate immune deficiency of extremely premature neonates can be reversed by interferon-&#x3b3;</article-title>. <source>PloS One</source>. (<year>2012</year>) <volume>7</volume>:<fpage>e32863</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0032863</pub-id>, PMID: <pub-id pub-id-type="pmid">22427899</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Buck</surname> <given-names>C</given-names></name>
<name><surname>Bundschu</surname> <given-names>J</given-names></name>
<name><surname>Gallati</surname> <given-names>H</given-names></name>
<name><surname>Bartmann</surname> <given-names>P</given-names></name>
<name><surname>Pohlandt</surname> <given-names>F</given-names></name>
</person-group>. 
<article-title>Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection</article-title>. <source>Pediatrics</source>. (<year>1994</year>) <volume>93</volume>:<page-range>54&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1542/peds.93.1.54</pub-id>, PMID: <pub-id pub-id-type="pmid">8265324</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Panero</surname> <given-names>A</given-names></name>
<name><surname>Pacifico</surname> <given-names>L</given-names></name>
<name><surname>Rossi</surname> <given-names>N</given-names></name>
<name><surname>Mancuso</surname> <given-names>G</given-names></name>
<name><surname>Stegagno</surname> <given-names>M</given-names></name>
<name><surname>Chiesa</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>Interleukin 6 in neonates with early and late onset infection</article-title>. <source>Pediatr Infect Dis J</source>. (<year>1997</year>) <volume>16</volume>:<page-range>370&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/00006454-199704000-00007</pub-id>, PMID: <pub-id pub-id-type="pmid">9109138</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>de Bont</surname> <given-names>ES</given-names></name>
<name><surname>Martens</surname> <given-names>A</given-names></name>
<name><surname>van Raan</surname> <given-names>J</given-names></name>
<name><surname>Samson</surname> <given-names>G</given-names></name>
<name><surname>Fetter</surname> <given-names>WP</given-names></name>
<name><surname>Okken</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>Diagnostic value of plasma levels of tumor necrosis factor alpha (TNF alpha) and interleukin-6 (IL-6) in newborns with sepsis</article-title>. <source>Acta Paediatr</source>. (<year>1994</year>) <volume>83</volume>:<page-range>696&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1651-2227.1994.tb13121.x</pub-id>, PMID: <pub-id pub-id-type="pmid">7949797</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Silveira</surname> <given-names>RC</given-names></name>
<name><surname>Procianoy</surname> <given-names>RS</given-names></name>
</person-group>. 
<article-title>Evaluation of interleukin-6, tumour necrosis factor-alpha and interleukin-1beta for early diagnosis of neonatal sepsis</article-title>. <source>Acta Paediatr</source>. (<year>1999</year>) <volume>88</volume>:<page-range>647&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/08035259950169314</pub-id>, PMID: <pub-id pub-id-type="pmid">10419250</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Latifi</surname> <given-names>SQ</given-names></name>
<name><surname>O&#x2019;Riordan</surname> <given-names>MA</given-names></name>
<name><surname>Levine</surname> <given-names>AD</given-names></name>
</person-group>. 
<article-title>Interleukin-10 controls the onset of irreversible septic shock</article-title>. <source>Infect Immun</source>. (<year>2002</year>) <volume>70</volume>:<page-range>4441&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/IAI.70.8.4441-4446.2002</pub-id>, PMID: <pub-id pub-id-type="pmid">12117955</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname> <given-names>PC</given-names></name>
<name><surname>Li</surname> <given-names>K</given-names></name>
<name><surname>Wong</surname> <given-names>RP</given-names></name>
<name><surname>Chui</surname> <given-names>K</given-names></name>
<name><surname>Wong</surname> <given-names>E</given-names></name>
<name><surname>Li</surname> <given-names>G</given-names></name>
<etal/>
</person-group>. 
<article-title>Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source>. (<year>2003</year>) <volume>88</volume>:<page-range>F209&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/fn.88.3.f209</pub-id>, PMID: <pub-id pub-id-type="pmid">12719394</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Khaertynov</surname> <given-names>KS</given-names></name>
<name><surname>Boichuk</surname> <given-names>SV</given-names></name>
<name><surname>Khaiboullina</surname> <given-names>SF</given-names></name>
<name><surname>Anokhin</surname> <given-names>VA</given-names></name>
<name><surname>Andreeva</surname> <given-names>AA</given-names></name>
<name><surname>Lombardi</surname> <given-names>VC</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparative assessment of cytokine pattern in early and late onset of neonatal sepsis</article-title>. <source>J Immunol Res</source>. (<year>2017</year>) <volume>2017</volume>:<elocation-id>8601063</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2017/8601063</pub-id>, PMID: <pub-id pub-id-type="pmid">28367457</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ye</surname> <given-names>Q</given-names></name>
<name><surname>Du</surname> <given-names>LZ</given-names></name>
<name><surname>Shao</surname> <given-names>WX</given-names></name>
<name><surname>Shang</surname> <given-names>SQ</given-names></name>
</person-group>. 
<article-title>Utility of cytokines to predict neonatal sepsis</article-title>. <source>Pediatr Res</source>. (<year>2017</year>) <volume>81</volume>:<page-range>616&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/pr.2016.267</pub-id>, PMID: <pub-id pub-id-type="pmid">27997530</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Leal</surname> <given-names>YA</given-names></name>
<name><surname>&#xc1;lvarez-Nemegyei</surname> <given-names>J</given-names></name>
<name><surname>Lavadores-May</surname> <given-names>AI</given-names></name>
<name><surname>Gir&#xf3;n-Carrillo</surname> <given-names>JL</given-names></name>
<name><surname>Cedillo-Rivera</surname> <given-names>R</given-names></name>
<name><surname>Velazquez</surname> <given-names>JR</given-names></name>
</person-group>. 
<article-title>Cytokine profile as diagnostic and prognostic factor in neonatal sepsis</article-title>. <source>J Matern Fetal Neonatal Med</source>. (<year>2019</year>) <volume>32</volume>:<page-range>2830&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/14767058.2018.1449828</pub-id>, PMID: <pub-id pub-id-type="pmid">29562764</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/107337">Andrea Fuso</ext-link>, Sapienza University of Rome, Italy</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/394039">Hugo Caire Castro-Faria-Neto</ext-link>, Oswaldo Cruz Foundation (Fiocruz), Brazil</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3216826">Rosario Linacero De La Fuente</ext-link>, Complutense University of Madrid, Spain</p></fn>
</fn-group>
</back>
</article>